Drug Type Universal CAR-T |
Synonyms Anti-EGFRvIII CAR-T cell therapy (Suzhou Maximum Biotech), AntiEGFRvIII CAR T cell therapy Suzhou Maximum Biotech, EGFRvIII CART cell therapy Suzhou Maximum Biotech + [2] |
Target |
Action antagonists |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | China | 01 Sep 2026 | |
| Glioma of Brain, Familial | Preclinical | China | 30 Jan 2022 |





